Literature DB >> 15711642

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

Bradley T Messmer1, Davorka Messmer, Steven L Allen, Jonathan E Kolitz, Prasad Kudalkar, Denise Cesar, Elizabeth J Murphy, Prasad Koduru, Manlio Ferrarini, Simona Zupo, Giovanna Cutrona, Rajendra N Damle, Tarun Wasil, Kanti R Rai, Marc K Hellerstein, Nicholas Chiorazzi.   

Abstract

Due to its relatively slow clinical progression, B cell chronic lymphocytic leukemia (B-CLL) is classically described as a disease of accumulation rather than proliferation. However, evidence for various forms of clonal evolution suggests that B-CLL clones may be more dynamic than previously assumed. We used a nonradioactive, stable isotopic labeling method to measure B-CLL cell kinetics in vivo. Nineteen patients drank an aliquot of deuterated water (2H2O) daily for 84 days, and 2H incorporation into the deoxyribose moiety of DNA of newly divided B-CLL cells was measured by gas chromatography/mass spectrometry, during and after the labeling period. Birth rates were calculated from the kinetic profiles. Death rates were defined as the difference between calculated birth and growth rates. These analyses demonstrated that the leukemic cells of each patient had definable and often substantial birth rates, varying from 0.1% to greater than 1.0% of the entire clone per day. Those patients with birth rates greater than 0.35% per day were much more likely to exhibit active or to develop progressive disease than those with lower birth rates Thus, B-CLL is not a static disease that results simply from accumulation of long-lived lymphocytes. Rather, it is a dynamic process composed also of cells that proliferate and die, often at appreciable levels. The extent to which this turnover occurs has not been previously appreciated. A correlation between birth rates and disease activity and progression appears to exist, which may help identify patients at risk for worsening disease in advance of clinical deterioration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15711642      PMCID: PMC548318          DOI: 10.1172/JCI23409

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

Review 1.  The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms.

Authors:  P Ghia; F Caligaris-Cappio
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

2.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

Authors:  Terry J Hamblin; Jenny A Orchard; Rachel E Ibbotson; Zadie Davis; Peter W Thomas; Freda K Stevenson; David G Oscier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia.

Authors:  D F Jelinek; R C Tschumper; S M Geyer; N D Bone; G W Dewald; C A Hanson; M J Stenson; T E Witzig; A Tefferi; N E Kay
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

4.  V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.

Authors:  Alexander Kröber; Till Seiler; Axel Benner; Lars Bullinger; Elsbeth Brückle; Peter Lichter; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

5.  Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia.

Authors:  L Granziero; P Ghia; P Circosta; D Gottardi; G Strola; M Geuna; L Montagna; P Piccoli; M Chilosi; F Caligaris-Cappio
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

6.  Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA.

Authors:  R A Neese; L M Misell; S Turner; A Chu; J Kim; D Cesar; R Hoh; F Antelo; A Strawford; J M McCune; M Christiansen; M K Hellerstein
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-07       Impact factor: 11.205

Review 7.  The pathologist's view point. Part I--indolent lymphomas.

Authors:  S A Pileri; S Ascani; E Sabattini; G Fraternali-Orcioni; S Poggi; M Piccioli; P P Piccaluga; B Gamberi; P L Zinzani; L Leoncini; B Falini
Journal:  Haematologica       Date:  2000-12       Impact factor: 9.941

8.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Authors:  T J Hamblin; Z Davis; A Gardiner; D G Oscier; F K Stevenson
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

9.  Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.

Authors:  Peter Chu; Dieter Deforce; Irene M Pedersen; Youngsoo Kim; Shinichi Kitada; John C Reed; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

10.  Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Liguang Chen; George Widhopf; Lang Huynh; Laura Rassenti; Kanti R Rai; Arthur Weiss; Thomas J Kipps
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

View more
  195 in total

1.  Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Daniel Mertens; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

Review 2.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

Review 3.  Molecular basis of CLL.

Authors:  Yuri Pekarsky; Nicola Zanesi; Carlo M Croce
Journal:  Semin Cancer Biol       Date:  2010-09-21       Impact factor: 15.707

Review 4.  Targeting the B-cell lymphoma/leukemia 2 family in cancer.

Authors:  Matthew S Davids; Anthony Letai
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

5.  Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients.

Authors:  Tycho Baumann; Riccardo Moia; Gianluca Gaidano; Julio Delgado; Adalgisa Condoluci; Neus Villamor; Anil Babu Payedimarri; Dolors Costa; Andrea Patriarca; Carlos Jiménez-Vicente; Davide Rossi; Emili Montserrat
Journal:  Leukemia       Date:  2021-02-04       Impact factor: 11.528

6.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Authors:  Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

7.  A stable isotope method for the simultaneous measurement of matrix synthesis and cell proliferation in articular cartilage in vivo.

Authors:  K W Li; S A Siraj; E W Cheng; M Awada; M K Hellerstein; S M Turner
Journal:  Osteoarthritis Cartilage       Date:  2009-02-07       Impact factor: 6.576

8.  RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.

Authors:  Jingjing Xu; Peng Zhou; Wenjuan Wang; Aining Sun; Feng Guo
Journal:  J Mol Med (Berl)       Date:  2013-09-17       Impact factor: 4.599

9.  The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

Authors:  K Balakrishnan; M Peluso; M Fu; N Y Rosin; J A Burger; W G Wierda; M J Keating; K Faia; S O'Brien; J L Kutok; V Gandhi
Journal:  Leukemia       Date:  2015-04-28       Impact factor: 11.528

10.  Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia.

Authors:  Stefano Molica; Gaetano Vitelli; Giovanna Cutrona; Katia Todoerti; Rosanna Mirabelli; Giovanna Digiesi; Diana Giannarelli; Isabella Sperduti; Matteo Molica; Massimo Gentile; Fortunato Morabito; Antonino Neri; Manlio Ferrarini
Journal:  Int J Hematol       Date:  2008-09-27       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.